dysfunction, including lactic acidosis, myopathy, cardiomyopathy, pancreatitis, peripheral neuropathy, and possibly lipodystrophy (Brinkman et al., 1998; Lewis & Dalakas, 1995) . HRF could be one of the results of mitochondrial dysfunction, but this link has not been clearly established yet.
Multiple subjective measures with established reliability and validity exist for the evaluation of HRF, yet attempts to identify reliable biomarkers for HRF have been unsuccessful (Aaronson et al., 1999; Dalakas et al., 1990; Piper et al., 1998) . For example, efforts to establish a correlation between immune suppression as measured by CD4 þ cell counts and HRF have resulted in conflicting results (Barroso & Lynn, 2002; Ferrando et al., 1998; Phillips et al., 2004; Sullivan & Dworkin, 2003) . Similar attempts to correlate HIV viral load, tumor necrosis factor a levels, hemoglobin, testosterone, or hepatic function with HRF have also failed to show an association (Barroso, Carlson, & Meynell, 2003; Darko et al., 1995; Moyle, 2002; Rabkin, Wagner, & Rabkin, 1999) .
The availability of minimally invasive tests to assess for mitochondrial toxicity would greatly facilitate understanding of the contribution of mitochondrial dysfunction to clinical syndromes. Mitochondrial dysfunction in the liver and muscle ultimately results in the development of lactic acidosis; however, venous lactate measurements are neither adequately sensitive nor specific enough for identification of early mitochondrial dysfunction (Blanco, Garcia-Benayas, Jose de la Cruz, Gonzalez-Lahoz, & Soriano, 2003; M. John et al., 2001) . Tissue biopsies are currently the gold standards for the evaluation and diagnosis of mitochondrial toxicity in muscle and liver, but these invasive tests are risky, painful, and impractical for routine and repeated evaluations. An alternative nonsurgical toxicity assay would improve clinical diagnoses tremendously (Authier, Chariot, & Gherardi, 2005; Bongiovanni & Tordato, 2007) .
We wanted to investigate whether peripheral CD14 þ monocytes could serve as producers of surrogate fatigue biomarkers instead of using more difficult to obtain tissue biopsies and provide the necessary information for objective diagnosis of HRF from mitochondrial dysfunction. Even if other fatigue gene networks are predominant in muscle or other tissues, CD14
þ cell gene expression patterns could be seen as a parallel metric of fatigue using these divergent markers, making development of a clinical assay for fatigue more attainable.
The purpose of this pilot study was to investigate the relationships between HRF and genomic expression markers of mitochondrial dysfunction in CD14 þ cells to generate fatigue-associated candidate genes. For this project, we used a mitochondrially specific gene expression microarray (Voss et al., 2008) to assay mitochondrial and nuclear genes related to mitochondrial function in CD14 þ cells of HIV/AIDS patients on ART regimens containing NTRIs with low and high fatigue compared to healthy controls.
Method
We describe the methodologies that we used in this study here, in Part 1 of this article. For an in-depth discussion of the statistical data analysis, see Part 2, ''Statistical Analysis.'' Investigators have used gene expression technology, which we relied upon for this study, to study samples including a mix of peripheral blood cells, purified cell fractions, and cerebrospinal fluid from patients with chronic fatigue syndrome (Cherry et al., 2002; Nolan et al., 2003) . Our recent development of a mitochondrial gene expression microarray has allowed us to investigate genes involved in fatigue-related symptom perceptions and to conduct a noninvasive assessment of mitochondrial involvement (Voss et al., 2008) . CD14 þ monocytes consist of two major subsets: A major nonactivated CD14þhi/CD16þlo population and a minor activated CD14þlo/CD16þhi population (Crowe, Zhu, & Muller, 2003; Ziegler-Heitbrock, 2007) . We chose to characterize the major nonactivated CD14 þ cells that are CD14 þ hi/CD16 þ lo, which we will call CD14 þ cells, obtained from peripheral blood to assay for mitochondrial dysfunction markers in HIV treatment-induced fatigue to avoid an obvious inflammatory signal. We selected this approach, using a purified cell type, so that variations in peripheral blood mononuclear cell fractions (PBMCs) between patients would not confound the expression data analysis. CD14
þ monocytes are easily obtained in high numbers from peripheral blood, are susceptible to HIV infection (Lambotte et al., 2000; Zhu et al., 2002) , and are thought to be a major reservoir for viral persistence during ART treatment (Alexaki, Liu, & Wigdahl, 2008; Crowe et al., 2003) .
During an NIH intramural natural history study, ''Assessing the Relationship Between Fatigue and Mitochondrial Toxicity in Patients with HIV/AIDS'' (05-CC-0127), with a focus on HRF and mitochondrial toxicity, we utilized samples from 10 HIV positive patients on NRTI-containing and proteaseinhibitor-sparing ART regimens and 5 healthy controls. We collected peripheral blood cells via aphaeresis for each patient. We evaluated fatigue in HIV patients using the revised 26-Item Piper Fatigue Scale, with fatigue scores varying between 0 and 10, where 0-3 was considered no fatigue, 4-7 moderate fatigue, and 8-10 severe fatigue (Piper et al., 1998) . For the purposes of this pilot study, we combined patients with moderate and severe fatigue scores of 4-10 into a high-fatigue group and considered patients with scores in the range 0-3 to be the low-fatigue group. In this substudy, we compared three categories of CD14 þ cell samples: Cells from HIV patients with high fatigue (n ¼ 5), from HIV patients with low fatigue (n ¼ 5), and from healthy controls (n ¼ 5). There were no significant differences in demographic characteristics or comorbidities between healthy controls and participants in the HIV patient groups (see Table 1 ).
CD14
þ Cell Isolation, RNA, and Protein Extraction CD14 þ cells were isolated from total PBMCs after aphaeresis with a negative CD14 þ isolation procedure, followed by CD14 þ positive cell sorting, according to the manufacturer's instructions. Average purity was 97.8 + 0.61% and average yield was 5.5 + 0.5 million cells. Cells were transferred to a QIAShredder MiniSpin Column (Qiagen, Valencia, CA) to sheer DNA then spun, and cell extracts were frozen and stored at À70
C until ribonucleic acid (RNA) extraction. RNA was extracted as previously described using the Qiagen RNeasy method (Voss et al., 2008) . The protein fraction was purified from the initial RNeasy column flow-through as specified by the manufacturer. Protein was precipitated out of the flow-through by addition of four volumes of ice-cold acetone. Proteins were pelleted by centrifugation and briefly air dried, washed with ice-cold absolute ethanol, and briefly air dried again. Pellets were resuspended in radioimmunoprecipitation assay (RIPA) buffer (Sigma-Aldrich, St. Louis, MO) and concentrations were determined by bicinchoninic acid (BCA) assay (Pierce, Rockford, IL).
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
RNA was reverse transcribed using the Promega Reverse Transcription Reaction System (Madison, WI) as specified by the manufacturer. PCR reactions were set up as per the manufacturer's instructions for DCt relative quantification (Applied Biosystems [AB], Foster City, CA). After thermal cycling, the amplification data were extracted from the AB 7300 data files for each 96-well plate and exported into Excel (Microsoft, Redmond, WA) for further processing. Briefly, for D Ct calculation per patient cDNA sample, the DCts were calculated by subtracting the gene-specific Ct triplicate average from the corresponding triplicate glyceraldehyde 3-phosphate dehydrogenase (GAPDH) endogenous control Ct average producing the normalized DCt value. For each gene per patient group, DCt averages were calculated with standard errors. Relative quotient (RQ) values between patient groups and control subjects were determined by the equation RQ ¼ 2 À(DCt patient CD14þ À DCt cntrl CD14þ) , as described by the manufacturer (AB). The AB primer/probe assays used were AGTR2 Hs02621316_s1, SULT2B1 Hs01105284_m1, ADCY7 Hs00936808_m1, CCL28 Hs00219797_m1, CFL2 Hs00368395_g1, PROK2 Hs00363716_m1, PAG1 Hs00179693_m1, IL21R Hs00222310_m1, and the GAPDH as endogenous control assay. Additionally, we first tried assays that did not amplify detectable AGTR2 (s1Hs00169126_m1) and SULT2B1 (Hs00190268_m1) message; the 5 0 end of these assays' amplicons were located more to the 5 0 direction in the messages of interest than the assays used above for these genes and therefore may have been too far from the poly A tail to amplify well from our oligo dT primed cDNA template mixtures.
Western Blotting
We loaded 20 μg CD14 þ cell total protein per well from fatigued and nonfatigued HIV patients and negative controls onto Nupage 4-12% Bis-Tris SDS-PAGE denaturing nonreducing polyacrylamide gels in 1 Â 2 -(N-morpholino)ethanesulfonic acid (MES) running buffer and separated them by size next to Novex Sharp Standard molecular weights using the Xcel Mini-Cell (Invitrogen, Carlsbad, CA). After running, proteins were transferred from gels onto polyvinylidene fluoride (PVDF) membranes using the Xcel blotter device as specified (Invitrogen). After transfer, filters were blocked, probed, washed, and developed using the WesternBreeze chromogenic immunodetection kit for mouse primary antibody (Invitrogen). Secondary antimouse antibody was visualized by the conjugated alkaline phosphatase catalysis of the BCPIP/NBT substrate to a chromogen product. Developed blots were photographed and quantified using a Gel Logic 200 imaging system and software (Kodak, Rochester, NY). The specificity of mouse monoclonal antihuman CFL2 primary antibody 6G9 (Sigma) was confirmed by Western blot probing against CFL2 recombinant protein H00001073-P01 (Novus Biologicals, Littleton, CO) and CFL2 transient overexpression lysate and negative control empty vector lysate (Origene, Rockville, MA) using primary antibody at 1 μg per ml (Invitrogen). Loading was quantified using mouse monoclonal b-actin antibody AC-74 (Sigma).
Microarray Analysis
We followed a microarray data analysis approach as previously described (Dobra, 2009; Dobra et al., 2004) . In the first step of this approach, we identified reduced sets of genes from the microarray data that are relevant for the phenotypes of interest. The validity of this selection method was quantified by the patient phenotype (i.e., fatigue and HIV status) prediction performance of the Bayesian model averaging classifier. These genes distinguished the phenotypes of interest but were not necessarily differentially expressed individually because we did not perform any tests proving differential expression. They, in effect, differentiate based on their combinatorial power as a set, not in isolation individually. In the second step of our approach, we developed association networks involving the reduced set of genes from the first step with the phenotype of interest. We constructed two distinct types of networks:
(a) Association networks, in which the links between two genes or between a gene and the phenotype represent strong pairwise associations. Here, the word association substitutes for the word correlation. In statistics, correlation refers to a linear association, while association can be any type of dependence, linear or nonlinear. (b) Liquid association networks, in which the association edges represent pairs of genes whose association changes with respect to the phenotype of interest.
The two types of networks complement each other. Two genes that are directly connected in an association network are likely to be functionally related (Butte, Tamayo, Slonim, Golub, & Kohane, 2000; Steuer, Kurths, Fiehn, & Weckwerth, 2003) . On the other hand, two genes are linked in a liquid association network if their relationship is influenced by the phenotype with respect to which the network was constructed (Li et al., 2007) . This inferential approach is based on a new stochastic search algorithm called the bounded mode stochastic search (BMSS; Dobra, 2009 ). These Affymetrix Probe Result File (CEL) files were preprocessed (i.e., background corrected and normalized) using Guanine Cytosine Robust Multi-array Average (Z. Wu & Irizarry, 2005; Z. Wu, Irizarry, Gentleman, Murillo, & Spencer, 2004) . After the removal of the 112 control probes included on the chip, the resulting data set comprised of 4,712 probes. The data were confirmed with real-time PCR experiments for several genes.
Results

Quantitative RT-PCR Replication of Array Results
Our microarray expression analysis demonstrated that there were gene association networks that differentiated between the patient subgroups ( Table 2) . To confirm the microarray data and expression patterns between patient groups, we performed real-time quantitative RT-PCR (qRT-PCR) on the same RNA samples used for our microarray analyses. We chose eight genes from the fatigue association list (Table 3 ) with higher Kendall t values differentiating HIVþ high fatigue versus HIVþ low-fatigue patients for this analysis. These fatigue liquid association-identified genes were CFL2, SULT2B1, PAG1, AGTR2 (high positive association with fatigue), and CCL28, PROK2, IL21R, ADCY7 (high negative association with fatigue; Tables 4 and 5). All abbreviations used herein are official NCBI database gene names.
We were able to detect all of the selected genes by qRT-PCR (Tables 4 and 5 ). We needed to utilize an additional second set of primer/probes to detect target genes AGTR2 and SULT2B1. The amplicons of the second primer/probe sets were located more to the 3 0 ends for these genes' messages compared to the more 5 0 region of the previous primer/probe sets we had tried (see Method section for primer codes). Moderate expression genes such as CFL2, PROK2, and PAG1 correlated between microarray raw expression intensity and qRT-PCR. We were unable to establish a correlation for several liquid-association genes, including SULT2B1, IL21R, and ADCY7, between microarray intensity and qRT-PCR RQ data between patient subsets at the lowest mRNA expressions level (Table 4) . We confirmed the increased expression of CFL2 by Western blot and found a linear increase in expression of the protein from HIVÀ to HIVþ low fatigued to HIVþ patients with high fatigue (Figure 1 ).
Genes Associated With HRF
We grouped HRF genes into broad classes by protein function or cellular location, some with overlapping constituents, using information from the publicly available protein function databases (OMIM, Genecards, and KEGG). Note that positive fatigue correlation is indicated by italics while negative correlation is indicated by normal font type. Classes were: RNA and DNA binding (CHD1L, HLCS, GSPT1, DDX19B, and SBNO1), mitochondrial function (CHD1L,TIMM17B, GSR, ALDOB, IMMT, SLC25A26), cell migration and activation (CFL2, MYH10, PAG1), cytokine signaling (IL21R, CCL28, IL7R, B2M), cell cycle and growth (GSPT1, SRP14, UGCG), hormone metabolism (SULT2B1, HSD17B3, PROK2), apoptosis (AGTR2), G protein signaling (AGTR2, ADCY2), lipid/cholesterol metabolism (ATP10A, ELA3B, FABP4); and endoplasmic reticulum (ER) protein transport (VPS13A, DPM1). We confirmed several of the significant genes with RT-PCR. Many of these genes have already been implicated in HIV pathology.
SULT2B1 is the gene most strongly associated with HRF status. Hallmarks of progressive HIV disease include symptoms such as persistent fatigue, loss of muscle mass, loss of sexual function, and many other testosterone driven disorders. SULT2B1 is a key gene in androgen synthesis pathways, and investigators have identified gonadal and adrenal androgen deficiencies in people living with HIV disease (Croxson et al., 1989; Honour, Schneider, & Miller, 1995) . Testosterone-replacement therapies have improved fatigue in men living with HIV (Rabkin, Wagner, McElhiney, Rabkin, & Lin, 2004) . PROK2 is a small 88-amino acid secreted peptide and G-protein coupled recepter (GPCR) agonist that regulates a variety of metabolic pathways and is highly expressed in the monocyte lineage (Monnier & Samson, 2008) . Most relevant to fatigue, gene-targeting experiments in mice show that PROK2, a downregulated gene, controls torpor, attenuates circadian rhythms, and disrupts normal sleep patterns (Gottlieb, O'Connor, & Wilk, 2007; Jethwa et al., 2008; Monnier & Samson, 2008) .
Several mitochondrial genes, TIMM17B and IMMT/mitofilin, are mitochondrial membrane proteins involved in translocation of proteins into the mitochondrial matrix (Schulke et al., 1999) . IMMT/mitofilin is an inner membrane protein and plays a critical role in the organization of mitochondrial cristae morphology (G. B. John et al., 2005) . Downregulation by siRNA leads to decreased cellular proliferation and increased apoptosis, with increased reactive oxygen species production and membrane potential (G. B. John et al., 2005) . IMMT/mitofilin also binds to PARP-1 and forms a complex inside the inner membrane, translocating PARP-1 into mitochondria; PARP-1 then is involved in mitochondrial DNA damage signaling and repair through a protein complex also containing DNA ligase III (Rossi et al., 2009) . TIMM17B is part of a protein complex that translocates proteins into the mitochondrial matrix and is necessary for cellular viability (Schulke et al., 1999) . In addition, we found immune genes such as IL21R, CCL28, IL7R, and B2M to be expressed in HIV patients with HRF compared to patients without, suggesting a connection between immune activation and HRF.
Several genes identified in the comparison of high and low fatigue also play a role in HIV disease progression. Higher serum levels of B2M, the MHC-I b chain protein, have been associated with HIV disease progression (Mocroft et al., 1997) . Similarly, investigators have found higher levels of CCL28 in blood and other fluids from HIV-infected patients compared to healthy subjects (Piacentini, Fenizia, Naddeo, & Clerici, 2008) . Chen et al. (2009) recently showed that CHDL1 inhibits apoptosis by binding to the transcription factor Nur77 and inhibiting transport of Nur77 into the mitochondria. Nur77, itself, is implicated in apoptosis of thymocytes and T cells, indicating that CHDL1 may regulate a complex apoptotic Wu et al., 2008) . When in an activated state, ADF proteins destabilize the F-actin filament web under the cell membrane by converting F-actin to G-actin. Most studies on cofilins and HIV have focused on T-cell infection, during which the HIV coreceptor CXCR4 is activated by binding to the HIV protein gp120. This process initiates F-actin depolymerization by a signaling pathway downstream from CXCR4 that activates cofilin through dephosporylation at a regulatory residue. This activation of cofilin allows HIV to penetrate through the now porous actin cortical web into the cytoplasm and eliminates a natural cellular cytoskeletal barrier to HIV infection (Yoder et al., 2008) . Once infection is established however, the HIV protein NEF inhibits cofilin activation by enhancing Pak2 kinase activity and phosphorylating cofilin. This inhibition of cofilin enhances F-actin stability, diminishing cell motility (Stolp et al., 2009 ). The action of CFL2 in CD14 þ cells is uncharacterized at this point, but similar mechanisms are suspected. PAG1 is a transmembrane protein with a long intracellular domain that was first identified in lipid rafts, where cell signaling proteins are concentrated, and is most highly expressed in the immune system (Svec, 2008) . Interestingly, PAG1 is considered a scaffolding protein that serves as an indirect connector between cytoskeletal F-actin and the cell membrane and brings together signaling molecules in close proximity to each other (Itoh et al., 2002) . PAG1 had the opposite expression pattern in our study to CFL2 and was higher in nonfatigued normal patients than in HIVþ patients. Overexpression experiments in T cells show that PAG1 inhibits cell activation and immune synapse formation. It also inhibits B and other immune cell activation (Horejsi, 2004; Svec, 2008) . Investigators posit that activated PAG1 inhibits signaling and cell migration by stabilizing the attachment of lipid rafts to the F-actin web at the cell membrane, keeping the cytoskeleton in an inactive mode (Saibil, Deenick, & Ohashi, 2007) .
Genes Associated With HIV Disease
This study confirms genes in CD14 þ cells previously identified to be related to HIV disease. The HIV disease signature contains genes that can be grouped into two broad sets: Inflammation and signaling pathways. The most organized cluster has a hub around OSBPL7, with immune function genes HLA-DQA1, CXCL12 (chemokine agonist of HIV coreceptor CXCL4), GOT1, and the apoptotic gene SIVA1. These inflammatory regulator genes are associated with the key cell membrane signal integrating genes ADCY2 and PLCb1. Other regulators of cell behavior are PPARa, involved in cell growth and differentiation; CASC4, which is associated with HER-2/ neu proto-oncogene overexpression; HIPK2, a serine/threonine nuclear kinase that interacts with homeodomain transcription factors to inhibit cell growth and promote apoptosis; and GFRA2 (glial cell line-derived neurotrophic factor 2), a potent neurotrophic factor that plays a key role in the control of neuron survival and differentiation. NME6, though a metabolic enzyme with nucleoside diphosphate kinases activity involved in synthesis of nucleoside triphosphates other than ATP, is an inhibitor of P53-induced apoptosis. Histone deacetylase (HDAC) type 6 was positively associated with HIV infection in the present study, confirming previous findings (Archin et al., 2009) . CXCL12 is a potent inhibitor of HIV cellular infectivity through blocking adhesion of HIV to its coreceptor CXCR4 (Altenburg, Jin, Alkhatib, & Alkhatib, 2010) .
We found several novel gene associations with HIV status from our array analyses that warrant further study. Some of these genes are involved in regulation of translation and transcription, such as TXLNB (TaxilinB), a member of a gene family that binds to syntaxins, and the NAC protein (nascent polypeptide-associated complex). NAC is part of a heterodimer complex that attaches to nascent polypeptide chains emerging from ribosomes and prevents polypeptide transfer to the ER. YAF2 is a zinc finger protein involved in negative regulation of muscle-restricted genes. MYC is a binding partner of YAF2 and also member of the E2F6.com-1 complex, a repressive complex that methylates ''Lys-9'' of histone H3, suggesting that it is involved in chromatin-remodeling. Another de novo gene in connection to HIV infection is GARS, a glycyl-tRNA synthetase shown to be a target of autoantibodies in human autoimmune diseases, including polymyositis and dermatomyositis. Two of the HIV-associated genes are involved in fatty acid metabolism, the novel ACAD9 and the much better understood PPARa. ACAD9 is a mitochondrial enzyme that catalyzes the initial rate-limiting step in the b oxidation of fatty acyl-CoA. PPARa regulates lipid metabolism and transcription of genes regulating fatty acid b oxidation. Finally, the signaling pathway members ADCY2 and PLCb1 are involved classically in the regulation of muscle contraction through G-protein coupled receptors. They are joined by other regulators of contraction here: TNNC1, which covers active sites for myosin on actin filaments and regulates actin/myosin interactions via calcium levels, and CHN1 (n-chimerin), a GTPase-activating protein for p21-rac and a phorbol ester receptor involved in ocular motor axon path finding (Zhu et al., 1993) . How they interact with HIV is currently not understood.
Discussion
Our main goal in this study was to identify candidate genes associated with HRF. While it was a pilot study and lacked sufficient power for absolute statistical confidence for the identified genes, it nonetheless has identified several hypotheses to explore in future studies with higher sample numbers that more unequivocally identify HRF-associated genes.
The etiology of fatigue is of fundamental interest to HIV clinicians and patients alike. Current investigators in fatigue We based the selection of our samples for the current analysis on either a high-or low-fatigue score in HRF. In future studies, we need to determine if the degree of expression of associated markers is related to the severity of symptom experience to establish a critical clinical measure for patient evaluation. In addition, analysis of gene expression in other diseases that induce fatigue would allow us to determine if any of the HRF-associated genes are specific to HIV disease or are more general markers of fatigue status.
While comparison of our microarray data to independent qRT-PCR quantifications matched for the higher expression genes, several very low expression genes were not validated. The low expression array data should be interpreted with caution. Published data show that low expression genes have the least reproducibility between oligonucleotide arrays and qRT-PCR, while moderate expression genes have the highest reproducibility between these platforms. Moreover, we do not necessarily expect Kendal's ts calculated from liquid association analysis between gene expression and a phenotype to directly correspond to microarray raw intensity levels or to qRT-PCR RQ differences between patient groupings. Liquid association relationships are developed using Bayesian statistical regressions that are not equivalent to more traditional t test statistical comparisons. The low expression genes, such as SULT2B1 and AGTR2, need to be further analyzed between additional sets of HRF patients to verify positive association with fatigue.
We have several questions that we want to explore in future research. HIV virus infects CD14 þ monocytes, and they provide a cell reservoir for HIV persistence even during successful HIV treatment with ART (Crowe et al., 2003) . Are the effects of HIV disease and ART additive in relationship to fatigue, and can these additive effects be observed in the molecular signatures? Are some of the mitochondrial genes identified in CD14 þ cells of HRF patients similarly expressed in other tissue types of HIV patients, particularly in skeletal muscle? While skeletal muscle, itself, is not infected with HIV, do ART-related and immunological effects from HIV disease play an important causative role in the development of fatigue symptoms? (Appay & Sauce, 2008; Fantuzzi, Belardelli, & Gessani, 2003) Certainly tissue macrophages can secrete inflammatory cytokines or apoptotic factors to surrounding tissue that would affect physiological processes in that tissue, or as circulating CD14 þ monocytes while in the blood stream, they could also produce similar factors systemically. In fact, a major paradigm of HIV disease progression is long-term systemic immune activation, which is consistent with several genes identified in our HIV-associated gene set (Appay & Sauce, 2008; Centlivre, Sala, WainHobson, & Berkhout, 2007; Douek, 2007) .
The identification of disease-specific and general pathways regulating the etiology of fatigue could be clinically useful in patient treatment. It might be pertinent to the question of what effect hepatitis virus infection and clearance has in HRF. A number of HIV patients examined in this study had been exposed to either or both hepatitis B and C (HBV and HCV) viruses as evidenced from antibodies reactive against hepatitis proteins in the blood work. The scope of this study was not large enough to examine the effects of previous hepatitis infection on fatigue levels in HCF disease, but investigators could address this question in future research using a larger data set designed to examine the issue.
Conclusions
We have identified for the first time a potential network of genes in CD14 þ cells of HRF in ART-treated HIV patients compared to healthy controls. Furthermore, these genes may represent potential candidate biomarkers that could be useful diagnostically, as they are measurable in an easily accessible cell type, the CD14 þ cell. We accomplished our study aims by generating a number of hypotheses related to genes involved in HRF to follow up with larger samples sizes, comparisons between CD14 and other PBMC populations and an animal model system of HRF or at least with ART-induced mitochondrial dysfunction.
